Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
International Journal of Hematologic Oncology
|
August 31, 2019
Developments in chemotherapy for the treatment of acute myeloid leukemia
Mark W Drummond
Plos Computational Biology
|
September 15, 2009
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib
Jasmine Foo, Mark W Drummond, Bayard Clarkson, et al.
Stem Cells (Dayton, Ohio)
|
May 19, 2007
Concise review: Telomere biology in normal and leukemic hematopoietic stem cells
Mark W Drummond, Stefan Balabanov, Tessa L Holyoake, et al.
British Journal of Haematology
|
November 18, 2003
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission
Mark W Drummond, David Marin, Richard E Clark, et al.
Ejhaem
|
September 2, 2022
Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK
Lewis Carpenter, Patrick Rockenschaub, Grace B Hatton, et al.
Haematologica
|
October 17, 2009
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Dragana Milojkovic, Emma Nicholson, Jane F Apperley, et al.
JAMA Oncology
|
July 17, 2015
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial
Animesh Pardanani, Claire Harrison, Jorge E Cortes, et al.
Nature Medicine
|
December 7, 2021
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
Daniel J DeAngelo, Deepti H Radia, Tracy I George, et al.
Leukemia Research
|
December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆
Karen Yee, Cristina Papayannidis, Norbert Vey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2015
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff, Kevin R Kelly, Karen Yee, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
International Journal of Hematologic Oncology
|
August 31, 2019
Developments in chemotherapy for the treatment of acute myeloid leukemia
Mark W Drummond
Plos Computational Biology
|
September 15, 2009
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib
Jasmine Foo, Mark W Drummond, Bayard Clarkson, et al.
Stem Cells (Dayton, Ohio)
|
May 19, 2007
Concise review: Telomere biology in normal and leukemic hematopoietic stem cells
Mark W Drummond, Stefan Balabanov, Tessa L Holyoake, et al.
British Journal of Haematology
|
November 18, 2003
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission
Mark W Drummond, David Marin, Richard E Clark, et al.
Ejhaem
|
September 2, 2022
Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK
Lewis Carpenter, Patrick Rockenschaub, Grace B Hatton, et al.
Haematologica
|
October 17, 2009
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Dragana Milojkovic, Emma Nicholson, Jane F Apperley, et al.
JAMA Oncology
|
July 17, 2015
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial
Animesh Pardanani, Claire Harrison, Jorge E Cortes, et al.
Nature Medicine
|
December 7, 2021
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
Daniel J DeAngelo, Deepti H Radia, Tracy I George, et al.
Leukemia Research
|
December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆
Karen Yee, Cristina Papayannidis, Norbert Vey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2015
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff, Kevin R Kelly, Karen Yee, et al.
Page
of 2